1. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
   E.J. Blok et al, 2017, Cancer Treatment Reviews CrossRef
2. Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer.
   Chelain R Goodman et al, 2018, JAMA Oncol CrossRef
3. Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy
   Chuanli Ren et al, 2016, Int. J. Cancer CrossRef
4. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients
   Fausto Petrelli et al, 2015, Breast Cancer Res Treat CrossRef
5. Circulating Tumour Cells in Primary Disease: The Seed for Metastasis
   Noam Falbel Pondé et al, 2017 CrossRef
6. Expression and clinical value of PD‐L1 which is regulated by BRD4 in tongue squamous cell carcinoma
   Lu Zhao et al, 2019, J Cell Biochem CrossRef
7. Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients
   Kjersti Tjensvoll et al, 2019, BMC Cancer CrossRef
8. Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score
   Puneet Singh et al, 2020, Breast Cancer Res Treat CrossRef
9. The Role of Circulating Tumor Cells in Breast Cancer and Implications for Radiation Treatment Decisions
   Chelain R. Goodman et al, 2021, International Journal of Radiation Oncology*Biology*Physics CrossRef
10. uPA/PAI-1 et EPClin® : comparaison de leur impact sur la prise en charge des cancers du sein de pronostic intermédiaire
    P. Maniez et al, 2021, Gynécologie Obstétrique Fertilité & Sénologie  CrossRef
11. Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach
    Bradley M. Turner et al, 2021, Human Pathology Reports CrossRef
12. Liquid biopsy as a cancer biomarker-potential, and challenges
    Daniel C. Danila, 2022 CrossRef
13. Real-world utilization of the 21-gene assay in taiwanese female patients with early-stage breast cancer: Experience from a single institute
    Yi-Ching Huang et al, 2022, J Cancer Res Pract CrossRef
14. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing
    Bradley M. Turner et al, 2023, Cancers CrossRef
15. Association between 21-gene-assay and detection of disseminated tumor cells in patients with early breast cancer: results from the IRMA trial
    Léa L. Volmer et al, 2023, Breast Cancer Res Treat CrossRef
16. Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature
    Mehwish Mooghal et al, 2024, Breast Cancer�(Auckl) CrossRef
17. The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer
    Christian Jackisch et al, 2024, Breast Cancer Res Treat CrossRef